Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 20/20 | 0.98 |
| ▸ | F9 | P00740 | 1/20 | 0.72 |
| ▸ | PLG | P00747 | 8/20 | 0.64 |
| ▸ | PLAT | P00750 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30627535 | 0.99 | PLAU (1.00) | PLAUF9PLGPLAT | |
| SCHEMBL6437332 | 0.99 | PLAU (1.00) | PLAUF9PLGPLAT | |
| Hydrochloric Acid SCHEMBL6998046 | 0.98 | PLAU (0.98) | PLAUF9PLGPLAT | |
| Water SCHEMBL7083736 | 0.98 | PLAU (0.98) | PLAUF9PLGPLAT | |
| SCHEMBL6437325 | 0.78 | PLAU (0.65) | PLAUF9PLG | |
| SCHEMBL6433009 | 0.78 | PLAU (1.00) | PLAUF9PLGPLAT | |
| SCHEMBL7083910 | 0.78 | PLAU (1.00) | PLAUF9PLGPLAT | |
| Water SCHEMBL7083731 | 0.77 | PLAU (0.64) | PLAUF9PLG | |
| Hydrochloric Acid SCHEMBL6998042 | 0.77 | PLAU (0.64) | PLAUF9PLG | |
| SCHEMBL6437504 | 0.73 | PLAU (1.00) | PLAUPLGPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6645979-B2 | As antagonists of urinary-type plasminogen activator(uPA); for therapy of disorders mediated by uPA such as chronic dermal ulcer, bone restructuring, embryo implantation in the uterus, infiltration of immune cell into inflammatory sites, ovulation | PFIZER INC. | 2003-11-11 | — | — | US | disclosed |
| EP-1330439-A1 | (7-(3-CARBOXYPHENYL)-4-CHLOROISOQUINOLIN-1-YL)GUANIDINE | Pfizer Limited (GB) | 2003-07-30 | — | — | EP | disclosed |
| US-20020077336-A1 | (7-(3-Carboxyphenyl)-4-chloroisoquinolin-1-yl)guanidine | PFIZER INC. | 2002-06-20 | — | — | US | disclosed |
| WO-2002036571-A1 | (7-(3-CARBOXYPHENYL)-4-CHLOROISOQUINOLIN-1-YL)GUANIDINE | PFIZER LIMITED (GB) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077336-A1 | (7-(3-Carboxyphenyl)-4-chloroisoquinolin-1-yl)guanidine | GMPS, UGT1A7, UGT2B7 | PLAU 3226/4885F9 2576/4885PLG 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.